Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Other operating expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Danaher

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines. The Diagnostics segment is composed of analytical instruments, reagents, consumables, software, and services that hospitals, physicians' offices, reference laboratories, and other critical care settings use to diagnose disease and make treatment decisions. The Environmental & Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Danaher exceeds Q1 expectations, eyes growth in China market

Danaher's Q1 performance showcased resilience and strategic focus amidst revenue challenges.
The company's strengths in operational efficiency and strategic initiatives position it well for future growth.
Challenges in certain segments highlight the need for adaptive strategies and market diversification.
Opportunities in China's market recovery and operational improvements offer avenues for sustained growth.

Danaher reports resilient Q2 performance amid COVID-19 challenges

Danaher navigated Q2 2023 with resilience amidst COVID-19 challenges, showcasing strong financial performance and strategic focus. While facing revenue declines in certain segments, the company remains confident in its ability to create shareholder value and improve human health. Capital deployment, inventory management, and market alignment present opportunities for future growth.

Danaher reports Q3 revenue decline, eyes growth in diagnostics market

Danaher's Q3 performance showed revenue declines in key segments, but strategic moves like spin-offs and acquisitions indicate a focus on long-term growth. Challenges in China and revenue projections for the year present short-term hurdles, while opportunities in drug development and diagnostics offer potential for future expansion.

Danaher reports solid 2023 performance, anticipates gradual growth in 2024

Danaher Corporation's 2023 performance showcased strong full-year sales and operating profit margin, but the fourth quarter saw a decline in core revenue. The company is focused on enhancing its portfolio and strengthening its growth trajectory, with expectations for improved growth in the second half of 2024. Challenges include the need for gradual improvement in demand and the pace of recovery in different geographies.

Danaher beats Q1 expectations, eyes growth in Diagnostics segment

Danaher's Q1 2024 performance exceeded expectations, driven by strong Diagnostics segment growth.
While facing challenges in bioprocessing and margin expectations, the company remains focused on long-term sustainability.
Opportunities lie in anticipated growth in Diagnostics and bioprocessing segments, with a focus on innovation and recurring revenue.
Continuous monitoring of market trends and global capabilities position Danaher for future success.

Danaher beats Q2 expectations, eyes growth amid revenue challenges

Danaher Corporation delivered a strong performance in Q2 2024, surpassing revenue, earnings, and cash flow expectations, driven by bioprocessing and Cepheid's success.
While facing challenges such as core revenue declines in the biotechnology segment, the company maintains a solid financial position with strong free cash flow.
Opportunities lie in leveraging positive momentum in key segments, expanding market share, and enhancing sustainability efforts to drive future growth and profitability.
Overall, Danaher's strategic focus on operational efficiency and growth areas positions it well to navigate challenges and capitalize on opportunities in the evolving market landscape.

Danaher surpasses Q3 expectations, eyes China stimulus for growth

Danaher's Q3 performance exceeded expectations, driven by strong results in biotechnology and Cepheid's core revenue growth.
While facing challenges in China market dynamics and core revenue declines in certain segments, the company remains optimistic about future growth.
Opportunities lie in leveraging China's stimulus for 2025 outlook and strategic M&A activities to fuel long-term growth and innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Crane Company

CR vs. DHR: Which Stock Is the Better Value Option?

CR vs. DHR: Which Stock Should Value Investors Buy Now?

Danaher (DHR) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Is Danaher (DHR) a Solid Growth Stock? 3 Reasons to Think " Yes "

Danaher Corporation (DHR) CEO Tom Jo on Q2 2019 Results - Earnings Call Transcript

Danaher's (DHR) second-quarter 2019 results benefit from growth in organic sales, acquired assets and DBS initiatives. Furthermore, the company raises its projection for the current year.

Danaher (DHR) Beats on Q2 Earnings and Sales, Ups Guidance

Danaher (DHR) delivered earnings and revenue surprises of 3.48% and 1.40%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Danaher (DHR) Surpasses Q2 Earnings and Revenue Estimates

Danaher (NYSE: DHR) reported second-quarter earnings of $1.19 per share, which beat the analyst consensus estimate of $1.16.

Danaher Reports Q2 Earnings Beat

Danaher (DHR) might gain from healthy demand for products, solid execution, acquired assets and Danaher Business System in the second quarter of 2019.  Forex woes remain concerning.

Will Danaher's (DHR) Products & Buyouts Drive Q2 Earnings?

AAR CORP.

Lowe's

QUALCOMM

Constellation Brands

Spiros Segalas (Trades, Portfolio), the manager of the Harbor Capital Appreciation Fund, released his second-quarter portfolio earlier this week, listing nine new positions.

Spiros Segalas’ Top 5 Buys of the 2nd Quarter

Another strong year and a transformational acquisition are in progress for one of the most admired industrial companies in the U.S.

Why Danaher Stock Soared Nearly 40% in the First Half of 2019

Danaher’s total return over-performed the Dow average for my 54 month test period by 73.30%, which is great for a company that has increased revenues, earnings, and dividends.

Danaher: Buy For Total Return, But It May Be Overvalued

Danaher (DHR) plans to create a separate dental company Envista, which will be listed on the New York Stock Exchange, and is likely to employ 12,000 people globally.

Danaher (DHR) Names New Dental Company Envista Holdings

BB&T

Centene

Salesforce

Tableau Software

First Data

Fiserv

General Electric

Newmont Mining

Pfizer

WellCare Health Plans

The $28 billion acquisition is the eighth-largest bank deal of all time. It’s expected to close in the fourth quarter.

The 7 Best Acquisitions of 2019

Agilent Technologies

Avantor Inc.

Thermo Fisher Scientific

Investing in the life sciences tool sector can be tricky, but according to the financial services firm Janney, the investing gain will be a result of finding the right secular trend in its own sector that comes from exposure to the production of biological therapeutics.

One Firm Sees Up to 45% Upside in Top Companies in Life Sciences Tools

Danaher (DHR) stands to gain from solid product portfolio, acquisitive nature and shareholder-friendly policy. High costs and debts as well as forex woes remain concerning.

Here's Why it is Worth Holding on to Danaher (DHR) Stock Now

American Express

GlaxoSmithKline

Lockheed Martin

Rio Tinto plc Sponsored

Starbucks

According to the GuruFocus All-in-One Screener, the following companies look cheap since they are trading with low price-sales ratios.

6 Guru Stocks With Low Price-Sales Ratios

Roper Technologies

Here's what makes Roper Technologies and Danaher so special in the stock market.

2 Industrial Stocks With a Killer Advantage

American Electric Power Company

Berry Petroleum Corp.

Fortive

Stanley Black & Decker

SWP Growth & Income ETF

Howard Marks (Trades, Portfolio)’ Oaktree Capital Management released its first-quarter portfolio earlier this month, listing eight new holdings.

The Top 5 Buys of Howard Marks’ Oaktree

CK Hutchison Holdings Ltd

CKHUY vs. DHR: Which Stock Is the Better Value Option?

CKHUY or DHR: Which Is the Better Value Stock Right Now?

Danaher (DHR) reported earnings 30 days ago. What's next for the stock?

Danaher (DHR) Up 3.4% Since Last Earnings Report: Can It Continue?

If there is one former Dow Jones industrial average leader that is in need of serious help, look no further than General Electric Co.

Can Danaher Walk Away From the Buyout of GE’s Biopharma Unit?

Danaher's management continues to transform the conglomerate, and the GE Biopharma deal looks like an even better value after a recent disclosure.

5 Reasons This Growth Stock Is Up 23% So Far in 2019

Blackrock Inc

Roche Holding AG

The Zacks Research Daily presents the best research output of our analyst team.

Top Research Reports for Roche, Danaher & BlackRock

The global science and technology company beat expectations in Q1. However, a pending acquisition caused Danaher to cut its full-year outlook.

Danaher's Q1 Looked Good, and a Big Acquisition Is on the Way

Danaher Corporation (DHR) CEO Tom Joyce on Q1 2019 Results - Earnings Call Transcript

News for Danaher Stock (DHR)